Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractIn April 2020, the US Food and Drug Administration granted emergency use authorization for certain medical devices to be used in patients with coronavirus disease 2019 (CO-VID-19). This included extracorporeal blood purification devices. This narrative review will give a brief overview regarding some of the extracorporeal devices that could be used to treat COVID-19 patients, including the Seraph® 100 Microbind® Affinity Blood Filter, produced by ExThera Medical (Martinez, CA, USA), first licensed in the European Economic Area in 2019. The Seraph® 100 contains ultrahigh molecular weight polyethylene beads with end point-attached heparin and is approved for the reduction of pathogens from the bloodstream either as a single agent or as an adjunct to conventional anti-infective agents. Bacteria, viruses, fungi, and toxins have been shown to bind to the immobilized heparin in a similar way to the interaction with heparan sulfate on the cell surface. This binding is nonreversible and as such, the pathogens are removed from the bloodstream. In this review, we describe the pathophysiological basis and rationale for using heparin for pathogen removal from the blood as well as exploring the technology behind the adaptation of heparin to deprive it of its systemic anticoagulant activity. In addition, we summarize the in vitro data as well as the available preclinical testing and published clinical reports. Finally, we discuss the enormous potential of this technology in an era of increasing antibiotic resistance and high mortality associated with sepsis and consider the application of this as a possible treatment option for COVID-19.
CitationBlood Purif. 2020;1-7. doi:10.1159/000508647.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- <i>In vitro</i> elimination of anti-infective drugs by the Seraph<sup>®</sup> 100 Microbind<sup>®</sup> affinity blood filter.
- Authors: Schmidt JJ, Eden G, Seffer MT, Winkler M, Kielstein JT
- Issue date: 2020 Jun
- Elimination of <i>Staphylococcus aureus</i> from the bloodstream using a novel biomimetic sorbent haemoperfusion device.
- Authors: Seffer MT, Eden G, Engelmann S, Kielstein JT
- Issue date: 2020 Aug 24
- Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter.
- Authors: Olson SW, Oliver JD, Collen J, Bunin J, Gleeson TD, Foster BE, Simmons MP, Chen HW, Ficke JB, Brown TE, Nau MT, Cebula BR, Kielstein J, Chung KK
- Issue date: 2020 Aug
- Clearance of chloroquine and hydroxychloroquine by the Seraph® 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients.
- Authors: Seffer MT, Martens-Lobenhoffer J, Schmidt JJ, Eden G, Bode-Böger SM, Kielstein JT
- Issue date: 2020 Jun 19
- Low-density lipoprotein apheresis: an evidence-based analysis.
- Authors: Medical Advisory Secretariat.
- Issue date: 2007